Healthcare Business

153576724

Aegerion Pharmaceuticals Plunges to New 52-Week Low

Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) reported its third-quarter results Thursday after the market close as -$0.12 in earnings per share and $43.7 million in revenue, against Thomson Reuters consensus estimates ...
Read Full Story »
Hazmat

Lakeland Living Up to Production Promises

Lakeland Industries Inc. (NASDAQ: LAKE) gave an update Thursday on its business activity in the wake of the Ebola crisis. Globally the two top-selling protective suits for Lakeland are the ...
Read Full Story »
health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
145922793

Analyst’s Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings

While most of the top stocks in the S&P 500 are winding up the third-quarter reporting season, the specialty pharmaceutical stocks are ready to come from the on-deck circle and ...
Read Full Story »
Money background. Close-up.

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences Inc. (NASDAQ: GILD) reported its third-quarter results after the market close on Monday as $1.84 in earnings per share and $6.04 billion in revenue. That was against Thomson ...
Read Full Story »
biotech

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its third-quarter earnings after the U.S. markets close on Tuesday. Thomson Reuters has consensus estimates of $1.92 in earnings per shares ...
Read Full Story »
Pills

Amgen Posts 52-Week High, Beats It Again After Earnings

Drug maker Amgen Inc. (NASDAQ: AMGN) reported third-quarter 2014 results after markets closed Monday afternoon. The biotech company reported quarterly adjusted diluted earnings per share (EPS) of $2.30 and revenues ...
Read Full Story »
152498601

Pain Therapeutics and Durect Stung by Pfizer Move

Pain Therapeutics Inc. (NASDAQ: PTIE) shares dropped significantly in Monday’s trading on news that Pfizer Inc. (NYSE: PFE) had discontinued its agreement to develop and commercialize Pain’s Remoxy extended release ...
Read Full Story »
fda_logo

Sarepta Faces Major Hurdle, and Not From Ebola

In non-Ebola related news, Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot. The stock ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
merck

Merck Earnings Look Very Mixed in Major Restructuring

Merck & Co. Inc. (NYSE: MRK) reported its third-quarter results Monday morning as $0.90 in earnings per share and $10.6 billion in revenue. That was against Thomson Reuters consensus earnings ...
Read Full Story »
Hazmat

Lakeland Private Placement Comes at Severe Discount to Ebola Trade

Lakeland Industries Inc. (NASDAQ: LAKE) announced that it had entered into a definitive securities purchase agreement to raise approximately $11.2 million in a private placement of common stock, sold at ...
Read Full Story »
Pfizer

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

A Pfizer Inc. (NYSE: PFE) press release on Thursday evening was honestly given the wrong title by the company's investor relations department. The new release titled "Pfizer Declares 26-Cent Fourth-Quarter ...
Read Full Story »
DNA

Will Celgene Become the Next $100 Billion Biotech Stock?

Does Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech ...
Read Full Story »
135093244

Companies That Benefit as Sexually Transmitted Disease Cases Keep Growing

Although it is a subject many investors would like to avoid, for obvious reasons, the growth in the number of sexually transmitted diseases (or STDs, as they are called) is ...
Read Full Story »